A nausea drug called aprepitant helped when standard treatments failed for cannabinoid hyperemesis
A case report describes successful use of aprepitant (Emend) to treat cannabinoid hyperemesis syndrome after all other standard anti-emetic medications failed.
Quick Facts
What This Study Found
A patient with CHS who did not respond to common anti-emetics was successfully treated with aprepitant, an NK1 receptor antagonist typically used for chemotherapy-induced nausea.
Key Numbers
1 patient described. Aprepitant succeeded after all other common anti-emetics failed.
How They Did This
Single case report documenting clinical course and treatment response.
Why This Research Matters
CHS can be extremely difficult to treat, and standard anti-emetics often fail. This case suggests aprepitant may be a useful option when other treatments are ineffective.
The Bigger Picture
As CHS diagnoses increase, having more treatment options is critical. The NK1 receptor pathway represents a different mechanism than traditional anti-emetics, potentially explaining why it works when others don't.
What This Study Doesn't Tell Us
Single case report; effectiveness in one patient does not guarantee it will work for others. No control comparison or dosing optimization was performed.
Questions This Raises
- ?Would aprepitant work in a larger series of CHS patients?
- ?What is the optimal dosing regimen?
- ?Could it be used as first-line treatment for severe CHS?
Trust & Context
- Key Stat:
- Aprepitant succeeded after all standard anti-emetics failed
- Evidence Grade:
- Preliminary: single case report with no comparison group.
- Study Age:
- Published in 2019.
- Original Title:
- Emerging Role of Aprepitant in Cannabis Hyperemesis Syndrome.
- Published In:
- Cureus, 11(6), e4825 (2019)
- Database ID:
- RTHC-02219
Evidence Hierarchy
Describes what happened to one person or a small group.
What do these levels mean? →Frequently Asked Questions
What is aprepitant?
Aprepitant (brand name Emend) is a drug that blocks NK1 receptors involved in nausea and vomiting. It is primarily used to prevent chemotherapy-induced nausea.
Why don't normal anti-nausea drugs work for CHS?
The mechanism of vomiting in CHS appears to involve different pathways than typical nausea. Standard drugs target serotonin or dopamine receptors, while CHS may involve the endocannabinoid system and NK1 pathways, which is why aprepitant may be more effective.
Read More on RethinkTHC
- 420-sober-survival-guide
- CBT-cannabis-recovery
- THC-potency-increase-over-time
- cannabis-harm-reduction-opioids-alcohol-replacement
- cannabis-legalization-effects-health-data
- cannabis-relapse-cycle-pattern
- cannabis-tolerance-break-guide
- cold-turkey-vs-taper-quit-weed
- dating-sober-after-quitting-weed
- exercise-quitting-weed-anxiety-brain
- grieving-quitting-weed-loss
- help-someone-quit-weed
- how-to-cut-back-on-weed-moderation
- how-to-quit-weed
- journaling-weed-withdrawal
- marijuana-anonymous-SMART-recovery-compare
- meditation-mindfulness-weed-withdrawal
- microdosing-cannabis-benefits
- partner-still-smokes-weed
- partner-still-smokes-weed-quitting
- pink-cloud-sobriety-cannabis
- quit-weed-cold-turkey
- quit-weed-or-cut-back-which-is-better
- quit-weed-regret-went-back
- quitting-weed-20s
- quitting-weed-30s
- quitting-weed-after-years
- quitting-weed-during-crisis-divorce-job-loss
- quitting-weed-exercise
- quitting-weed-grief-loss-coping
- quitting-weed-legal-state
- quitting-weed-success-stories
- quitting-weed-triggers-environment
- relapsed-smoking-weed-what-to-do
- relapsed-weed
- safer-cannabis-use-guidelines
- should-i-quit-weed
- sober-music-festival-concert-without-weed
- sober-october-weed
- supplements-weed-withdrawal
- telling-friends-quitting-weed
- tolerance-break-weed
- weed-for-opioid-withdrawal
- weed-relapse-prevention-plan
- weed-relapse-why-it-happens
- weed-ritual-replacement
- weed-ruined-relationships
- weed-social-media-triggers-quit
Cite This Study
https://rethinkthc.com/research/RTHC-02219APA
Parvataneni, Swetha; Varela, Lionel; Vemuri-Reddy, Sireesha M; Maneval, Mandy L. (2019). Emerging Role of Aprepitant in Cannabis Hyperemesis Syndrome.. Cureus, 11(6), e4825. https://doi.org/10.7759/cureus.4825
MLA
Parvataneni, Swetha, et al. "Emerging Role of Aprepitant in Cannabis Hyperemesis Syndrome.." Cureus, 2019. https://doi.org/10.7759/cureus.4825
RethinkTHC
RethinkTHC Research Database. "Emerging Role of Aprepitant in Cannabis Hyperemesis Syndrome..." RTHC-02219. Retrieved from https://rethinkthc.com/research/parvataneni-2019-emerging-role-of-aprepitant
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.